Thinly traded cancer therapy developer Arcus Biosciences (RCUS +83.7%) is up big on almost a 7x surge in volume on reports that Gilead Sciences (GILD +2.0%) is mulling a “significant stake” in the company.
The company’s pipeline includes anti-TIGIT antibody AB154, PD-1 inhibitor zimberelimab and dual A2a/A2b adenosine receptor antagonist AB928.
Alphabet’s venture capital unit, GV, is also an investor.
Source: Seeking Alpha
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.